EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Recent Advances in the Management of Primary Sclerosing Cholangitis

David N Assis, Christopher L Bowlus

Clinical Gastroenterology and Hepatology · 2023-07 · 21 (8) · 2065-2075

DOI: 10.1016/j.cgh.2023.04.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-07. Verfasst von David N Assis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, Connecticut. Electronic address: david.assis@yale.edu. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Cholangiocarcinoma, Cholestasis, Bile Duct Neoplasms. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences, Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by fibroinflammatory damage to the biliary tree, typically in the setting of inflammatory bowel disease, with an increased risk of liver failure and cholangiocarcinoma. A complex pathophysiology, heterogeneity in clinical features, and the rare nature of the disease have contributed to the lack of effective therapy to date. However, recent innovations in the characterization and prognostication of patients with PSC, in addition to new tools for medical management and emerging pharmacologic agents, give rise to the potential for meaningful progress in the next several years. This review summarizes current concepts in PSC and highlights particular areas in need of further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingCholangiocarcinomaCholestasisBile Duct NeoplasmsHumansBile Ducts, Intrahepatic

Stichwörter der Autor:innen

CholangiocarcinomaClinical trialsMedical managementPrimary sclerosing cholangitis

Autor:innen und Institutionen

  • Yale School of Medicine, New Haven, Connecticut. Electronic address: david.assis@yale.edu.
  • University of California Davis Health, Sacramento, California.

Förderung

  • Gilead Sciences
  • Novo Nordisk

Zitieren

APA

Assis, D. N., & Bowlus, C. L. (2023). Recent Advances in the Management of Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 21(8), 2065-2075. https://doi.org/10.1016/j.cgh.2023.04.004

Vancouver

Assis DN, Bowlus CL. Recent Advances in the Management of Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology. 2023;21(8):2065-2075. doi:10.1016/j.cgh.2023.04.004

BibTeX
@article{Assis2023,
  author = {Assis, David N and Bowlus, Christopher L},
  title = {Recent Advances in the Management of Primary Sclerosing Cholangitis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  volume = {21},
  number = {8},
  pages = {2065--2075},
  doi = {10.1016/j.cgh.2023.04.004}
}
Kostenlos starten →